Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Accounts Payables (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Accounts Payables data on record, last reported at $5.4 million in Q3 2025.

  • For Q3 2025, Accounts Payables fell 72.54% year-over-year to $5.4 million; the TTM value through Sep 2025 reached $5.4 million, down 72.54%, while the annual FY2024 figure was $4.5 million, 4.93% up from the prior year.
  • Accounts Payables reached $5.4 million in Q3 2025 per PLX's latest filing, down from $6.7 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $19.6 million in Q3 2024 and bottomed at $3.1 million in Q3 2023.
  • Average Accounts Payables over 5 years is $9.7 million, with a median of $7.0 million recorded in 2021.
  • Peak YoY movement for Accounts Payables: skyrocketed 528.68% in 2024, then crashed 78.04% in 2025.
  • A 5-year view of Accounts Payables shows it stood at $7.0 million in 2021, then soared by 75.65% to $12.3 million in 2022, then tumbled by 64.8% to $4.3 million in 2023, then increased by 4.93% to $4.5 million in 2024, then rose by 18.57% to $5.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accounts Payables were $5.4 million in Q3 2025, $6.7 million in Q2 2025, and $4.1 million in Q1 2025.